ATE251304T1 - Verfahren und zusammensetzungen zur beobachtung der zellulären verarbeitung von beta-amyloid- vorläuferproteinen - Google Patents

Verfahren und zusammensetzungen zur beobachtung der zellulären verarbeitung von beta-amyloid- vorläuferproteinen

Info

Publication number
ATE251304T1
ATE251304T1 AT93907104T AT93907104T ATE251304T1 AT E251304 T1 ATE251304 T1 AT E251304T1 AT 93907104 T AT93907104 T AT 93907104T AT 93907104 T AT93907104 T AT 93907104T AT E251304 T1 ATE251304 T1 AT E251304T1
Authority
AT
Austria
Prior art keywords
beta
amyloid
app
secretion
monitored
Prior art date
Application number
AT93907104T
Other languages
English (en)
Inventor
Peter A Seubert
Dale B Schenk
Lawrence C Fritz
Original Assignee
Elan Pharm Inc
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27128086&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE251304(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Elan Pharm Inc, Lilly Co Eli filed Critical Elan Pharm Inc
Application granted granted Critical
Publication of ATE251304T1 publication Critical patent/ATE251304T1/de

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5091—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing the pathological state of an organism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5058—Neurological cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/0306—Animal model for genetic diseases
    • A01K2267/0312—Animal model for Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/0306—Animal model for genetic diseases
    • A01K2267/0318—Animal model for neurodegenerative disease, e.g. non- Alzheimer's
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4709—Amyloid plaque core protein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S436/00—Chemistry: analytical and immunological testing
    • Y10S436/811—Test for named disease, body condition or organ function
AT93907104T 1992-04-15 1993-03-03 Verfahren und zusammensetzungen zur beobachtung der zellulären verarbeitung von beta-amyloid- vorläuferproteinen ATE251304T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US86894992A 1992-04-15 1992-04-15
US07/965,971 US5441870A (en) 1992-04-15 1992-10-26 Methods for monitoring cellular processing of β-amyloid precursor protein
PCT/US1993/001817 WO1993021526A1 (en) 1992-04-15 1993-03-03 METHODS AND COMPOSITIONS FOR MONITORING CELLULAR PROCESSING OF β-AMYLOID PRECURSOR PROTEIN

Publications (1)

Publication Number Publication Date
ATE251304T1 true ATE251304T1 (de) 2003-10-15

Family

ID=27128086

Family Applications (1)

Application Number Title Priority Date Filing Date
AT93907104T ATE251304T1 (de) 1992-04-15 1993-03-03 Verfahren und zusammensetzungen zur beobachtung der zellulären verarbeitung von beta-amyloid- vorläuferproteinen

Country Status (14)

Country Link
US (3) US5441870A (de)
EP (1) EP0638172B1 (de)
JP (2) JP3974168B2 (de)
AT (1) ATE251304T1 (de)
AU (1) AU688726B2 (de)
CA (1) CA2118243C (de)
DE (1) DE69333225T2 (de)
DK (1) DK0638172T3 (de)
ES (1) ES2206455T3 (de)
FI (1) FI111546B (de)
NO (1) NO320067B1 (de)
NZ (1) NZ251053A (de)
PT (1) PT638172E (de)
WO (1) WO1993021526A1 (de)

Families Citing this family (172)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5525339A (en) * 1986-08-27 1996-06-11 Dms Pharmaceutical Inc. Isolated components of dense microspheres derived from mammalian brain tissue and antibodies thereto
US5441870A (en) * 1992-04-15 1995-08-15 Athena Neurosciences, Inc. Methods for monitoring cellular processing of β-amyloid precursor protein
US5837672A (en) * 1992-07-10 1998-11-17 Athena Neurosciences, Inc. Methods and compositions for the detection of soluble β-amyloid peptide
US6610493B1 (en) * 1993-06-17 2003-08-26 Brigham And Women's Hospital Screening compounds for the ability to alter the production of amyloid-β peptide
US5605811A (en) * 1992-10-26 1997-02-25 Athena Neurosciences, Inc. Methods and compositions for monitoring cellular processing of beta-amyloid precursor protein
EP0667959B1 (de) * 1992-10-26 2003-08-13 Elan Pharmaceuticals, Inc. Verfahren zur Identifizierung von Hemmstoffe der Produktion des beta-Amyloidpeptids
ATE198622T1 (de) 1993-10-27 2001-01-15 Elan Pharm Inc Transgene tiere, die app allele mit der schwedischen mutation beherbergen
US5589154A (en) * 1994-11-22 1996-12-31 Rutgers, The State University Of New Jersey Methods for the prevention or treatment of vascular hemorrhaging and Alzheimer's disease
US6017887A (en) * 1995-01-06 2000-01-25 Sibia Neurosciences, Inc. Peptide, peptide analog and amino acid analog protease inhibitors
US5804560A (en) * 1995-01-06 1998-09-08 Sibia Neurosciences, Inc. Peptide and peptide analog protease inhibitors
CA2221684A1 (en) * 1995-06-06 1996-12-12 Athena Neurosciences, Inc. Novel cathepsin and methods and compositions for inhibition thereof
US5783434A (en) * 1995-06-06 1998-07-21 Tung; Jay S. Cathepsin and methods and compositions for inhibition thereof
US5849711A (en) * 1995-06-06 1998-12-15 Athena Neurosciences, Inc. Cathepsin and methods and compositions for inhibition thereof
US6717031B2 (en) 1995-06-07 2004-04-06 Kate Dora Games Method for selecting a transgenic mouse model of alzheimer's disease
US6136530A (en) * 1995-11-29 2000-10-24 Texas Tech University Health Sciences Center Compositions and methods for assessing risk factors in Alzheimer's disease
WO1997021728A1 (en) 1995-12-12 1997-06-19 Karolinska Innovations Ab PEPTIDE BINDING THE KLVFF-SEQUENCE OF AMYLOID $g(b)
JPH09178743A (ja) * 1995-12-27 1997-07-11 Oriental Yeast Co Ltd 可溶性ａｐｐの定量法
GB9701684D0 (en) 1997-01-28 1997-03-19 Smithkline Beecham Plc Novel compounds
US8173127B2 (en) * 1997-04-09 2012-05-08 Intellect Neurosciences, Inc. Specific antibodies to amyloid beta peptide, pharmaceutical compositions and methods of use thereof
WO1999022781A2 (en) * 1997-10-31 1999-05-14 Children's Medical Center Corporation Bladder reconstruction
US6761888B1 (en) * 2000-05-26 2004-07-13 Neuralab Limited Passive immunization treatment of Alzheimer's disease
US20080050367A1 (en) * 1998-04-07 2008-02-28 Guriq Basi Humanized antibodies that recognize beta amyloid peptide
US6710226B1 (en) 1997-12-02 2004-03-23 Neuralab Limited Transgenic mouse assay to determine the effect of Aβ antibodies and Aβ Fragments on alzheimer's disease characteristics
US6913745B1 (en) 1997-12-02 2005-07-05 Neuralab Limited Passive immunization of Alzheimer's disease
US7790856B2 (en) 1998-04-07 2010-09-07 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize beta amyloid peptide
US6750324B1 (en) 1997-12-02 2004-06-15 Neuralab Limited Humanized and chimeric N-terminal amyloid beta-antibodies
US7588766B1 (en) 2000-05-26 2009-09-15 Elan Pharma International Limited Treatment of amyloidogenic disease
US7179892B2 (en) * 2000-12-06 2007-02-20 Neuralab Limited Humanized antibodies that recognize beta amyloid peptide
US6905686B1 (en) 1997-12-02 2005-06-14 Neuralab Limited Active immunization for treatment of alzheimer's disease
US6923964B1 (en) 1997-12-02 2005-08-02 Neuralab Limited Active immunization of AScr for prion disorders
US6787523B1 (en) * 1997-12-02 2004-09-07 Neuralab Limited Prevention and treatment of amyloidogenic disease
US7964192B1 (en) 1997-12-02 2011-06-21 Janssen Alzheimer Immunotherapy Prevention and treatment of amyloidgenic disease
TWI239847B (en) * 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
US20050059802A1 (en) * 1998-04-07 2005-03-17 Neuralab Ltd Prevention and treatment of amyloidogenic disease
US20030147882A1 (en) * 1998-05-21 2003-08-07 Alan Solomon Methods for amyloid removal using anti-amyloid antibodies
US7060670B1 (en) * 1999-05-05 2006-06-13 Neurochem (International) Limited Stereoselective antifibrillogenic peptides and peptidomimetics thereof
US20040167634A1 (en) * 1999-05-26 2004-08-26 Anthony Atala Prosthetic kidney and its use for treating kidney disease
US6787637B1 (en) 1999-05-28 2004-09-07 Neuralab Limited N-Terminal amyloid-β antibodies
UA81216C2 (en) * 1999-06-01 2007-12-25 Prevention and treatment of amyloid disease
US20070135337A2 (en) * 1999-11-29 2007-06-14 Neurochem (International) Limited Vaccine for the Prevention and Treatment of Alzheimer's and Amyloid Related Diseases
US20020094335A1 (en) * 1999-11-29 2002-07-18 Robert Chalifour Vaccine for the prevention and treatment of alzheimer's and amyloid related diseases
US6479064B1 (en) * 1999-12-29 2002-11-12 Children's Medical Center Corporation Culturing different cell populations on a decellularized natural biostructure for organ reconstruction
US6992081B2 (en) 2000-03-23 2006-01-31 Elan Pharmaceuticals, Inc. Compounds to treat Alzheimer's disease
CA2401749A1 (en) 2000-03-23 2001-09-27 Elan Pharmaceuticals, Inc. Compounds and methods to treat alzheimer's disease
AU5702201A (en) * 2000-04-13 2001-10-30 Mayo Foundation Abeta<sub>42</sub> lowering agents
EP1666452A2 (de) 2000-06-30 2006-06-07 Elan Pharmaceuticals, Inc. Verbindungen zur Behandlung der Alzheimerischen Krankheit
CA2410972A1 (en) * 2000-06-30 2002-01-10 Elan Pharmaceuticals, Inc. Compounds to treat alzheimer's disease
US6846813B2 (en) 2000-06-30 2005-01-25 Pharmacia & Upjohn Company Compounds to treat alzheimer's disease
PE20020276A1 (es) 2000-06-30 2002-04-06 Elan Pharm Inc COMPUESTOS DE AMINA SUSTITUIDA COMO INHIBIDORES DE ß-SECRETASA PARA EL TRATAMIENTO DE ALZHEIMER
US20030096864A1 (en) * 2000-06-30 2003-05-22 Fang Lawrence Y. Compounds to treat alzheimer's disease
FR2816411B1 (fr) * 2000-11-03 2003-07-04 Inst Nat Sante Rech Med Moyens de detection de la transformation pathologique de la proteine app et leurs applications
PE20020574A1 (es) 2000-12-06 2002-07-02 Wyeth Corp Anticuerpos humanizados que reconocen el peptido amiloideo beta
US7700751B2 (en) 2000-12-06 2010-04-20 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize β-amyloid peptide
US20030215896A1 (en) * 2001-04-25 2003-11-20 Yueming Li Gamma secretase substrates and in vitro assays
AU2002257162A1 (en) * 2001-04-30 2002-11-11 Eli Lilly And Company Humanized antibodies
US7196163B2 (en) * 2001-05-22 2007-03-27 Merk & Co., Inc. Assays using amyloid precursor proteins with modified β-secretase cleavage sites to monitor β-secretase activity
BR0210122A (pt) * 2001-06-01 2004-06-15 Elan Pharm Inc Composto ou um sal farmaceuticamente aceitável do mesmo, método para o tratamento ou prevenção de uma doença, uso do composto ou de seu sal, e, método para preparar o mesmo
WO2002100818A2 (en) 2001-06-13 2002-12-19 Elan Pharmaceuticals, Inc. Aminediols as agents for the treatment of alzheimer's disease
WO2003002122A1 (en) * 2001-06-27 2003-01-09 Elan Pharmaceuticals, Inc. Beta-hydroxyamine derivatives useful in treatment of alzheimer's disease
US20070213407A1 (en) * 2001-06-29 2007-09-13 Elan Pharmaceuticals And Pharmacia & Upjohn Company Llc Compounds to treat Alzheimer's disease
CA2453444A1 (en) * 2001-07-10 2003-01-23 Elan Pharmaceuticals, Inc. Diaminediols for the treatment of alzheimer's disease
US7053109B2 (en) * 2001-07-10 2006-05-30 Pharmacia & Upjohn Company Aminediols for the treatment of Alzheimer's disease
US7297553B2 (en) * 2002-05-28 2007-11-20 Nanosphere, Inc. Method for attachment of silylated molecules to glass surfaces
IL160208A0 (en) * 2001-08-31 2004-07-25 Neurochem Int Ltd Amidine derivatives for treating amyloidosis
EP1432674A2 (de) * 2001-10-04 2004-06-30 Elan Pharmaceuticals, Inc. Hydroxypropylamine
JP2005520791A (ja) 2001-11-08 2005-07-14 イーラン ファーマスーティカルズ、インコーポレイテッド Ｎ，ｎ’−置換−１，３−ジアミノ−２−ヒドロキシプロパン誘導体
JP2005509495A (ja) * 2001-11-16 2005-04-14 チルドレンズ メディカル センター コーポレーション 臓器の機能の増強
US20050080141A1 (en) * 2001-11-19 2005-04-14 Schostarez Heinrich J. Amino diols useful in the treatment of alzheimer's disease
US20050214763A1 (en) * 2002-02-14 2005-09-29 Rainer Hipfel Diagnostic and therapeutic use of an activator protein for vesicle secretion for neurodegenerative diseases
AU2003208857A1 (en) * 2002-02-14 2003-09-04 Evotec Neurosciences Gmbh Diagnostic and therapeutic use of caps
AU2003216370A1 (en) * 2002-02-27 2003-09-09 Merck And Co., Inc. Assays to monitor amyloid precursor protein processing
ES2392247T3 (es) * 2002-03-05 2012-12-07 Ramot At Tel-Aviv University Ltd. Compuesto inmunizante y método para inducir una respuesta inmune contra el sitio de escisión de la beta-secretasa de la proteína precursora de amiloide
MY139983A (en) 2002-03-12 2009-11-30 Janssen Alzheimer Immunotherap Humanized antibodies that recognize beta amyloid peptide
EP1575482A2 (de) * 2002-04-17 2005-09-21 Pharmacia & Upjohn Company LLC Zusammensetzungen und verfahren zur behandlung der alzheimer-krankheit
WO2004058686A1 (en) * 2002-04-30 2004-07-15 Elan Pharmaceuticals, Inc. Hydroxypropyl amides for the treatment of alzheimer’s disease
US20040146512A1 (en) * 2002-10-09 2004-07-29 Arnon Rosenthal Methods of treating Alzheimer's disease using antibodies directed against amyloid beta peptide and compositions thereof
KR100520495B1 (ko) * 2002-10-23 2005-10-11 한국과학기술연구원 베타아밀로이드 특이 단일 클론 항체 및 그의 제조방법
WO2004050609A1 (en) 2002-11-27 2004-06-17 Elan Pharmaceutical, Inc. Substituted ureas and carbamates
DE10303974A1 (de) 2003-01-31 2004-08-05 Abbott Gmbh & Co. Kg Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
WO2004069182A2 (en) * 2003-02-01 2004-08-19 Neuralab Limited Active immunization to generate antibodies to soluble a-beta
PE20050420A1 (es) * 2003-04-21 2005-06-13 Elan Pharm Inc Fenacilo 2-hidroxi-3-diaminoalcanos
JP2006524255A (ja) * 2003-04-21 2006-10-26 イーラン ファーマスーティカルズ、インコーポレイテッド ベンズアミド２−ヒドロキシ−３−ジアミノアルカン
WO2004100998A2 (en) * 2003-05-07 2004-11-25 General Electric Company Compositions and methods for non-invasive imaging of soluble beta-amyloid
US20040223912A1 (en) * 2003-05-07 2004-11-11 Montalto Michael Christopher Compositions and methods for non-invasive imaging of soluble beta-amyloid
PE20050627A1 (es) 2003-05-30 2005-08-10 Wyeth Corp Anticuerpos humanizados que reconocen el peptido beta amiloideo
US20060014790A1 (en) * 2004-01-21 2006-01-19 Varghese John Methods of treatment of amyloidosis using spirocyclohexane aspartyl-protease inhibitors
US7262223B2 (en) * 2004-01-23 2007-08-28 Neurochem (International) Limited Amidine derivatives for treating amyloidosis
EP1734961A2 (de) * 2004-03-09 2006-12-27 Elan Pharmaceuticals, Inc. Verfahren zur behandlung von amyloidose mit bicyclischen aspartyl-proteasehemmern
US20050239836A1 (en) * 2004-03-09 2005-10-27 Varghese John Substituted hydroxyethylamine aspartyl protease inhibitors
US20060014737A1 (en) * 2004-03-09 2006-01-19 Varghese John Methods of treatment of amyloidosis using bi-aryl aspartyl protease inhibitors
EP1734942A1 (de) * 2004-03-09 2006-12-27 Elan Pharmaceuticals, Inc. Substituierte harnstoff und carbamat, phenacyl-2-hydroxy-3-diaminoalkan, und benzamid-2-hydroxy-3-diaminoalkan aspartyl-proteasehemmer
WO2005087752A2 (en) * 2004-03-09 2005-09-22 Elan Pharmaceuticals, Inc. Substituted hydroxyethylamine aspartyl protease inhibitors
AU2005265354A1 (en) 2004-07-09 2006-01-26 Elan Pharmaceuticals, Inc. Oxime derivative hydroxyethylamine aspartyl-protease inhibitors
US7385085B2 (en) * 2004-07-09 2008-06-10 Elan Pharmaceuticals, Inc. Oxime derivative substituted hydroxyethylamine aspartyl protease inhibitors
MX2007000998A (es) * 2004-07-30 2007-07-11 Rinat Neuroscience Corp Anticuerpos dirigidos peptido beta-amiloide y procedimientos que usan los mismos.
JP2008511644A (ja) * 2004-08-27 2008-04-17 エラン ファーマシューティカルズ，インコーポレイテッド エタノール環式アミンアスパラギン酸プロテアーゼ阻害剤を用いて、アミロイドーシスを治療する方法
AU2005293752A1 (en) * 2004-10-13 2006-04-20 Ablynx N.V. Single domain camelide anti-amyloid beta antibodies and polypeptides comprising the same for the treatment and diagnosis of degenarative neural diseases such as Alzheimer's disease
PE20061401A1 (es) * 2004-12-15 2006-12-23 Neuralab Ltd ANTICUERPOS Aß PARA MEJORAR LA COGNICION
TW200636066A (en) 2004-12-15 2006-10-16 Elan Pharm Inc Humanized antibodies that recognize beta amyloid peptide
WO2006066089A1 (en) 2004-12-15 2006-06-22 Neuralab Limited Humanized amyloid beta antibodies for use in improving cognition
AU2006203819A1 (en) * 2005-01-07 2006-07-13 Roskamp Research Llc Compounds for inhibiting beta-amyloid production and methods of identifying the compounds
MY148086A (en) * 2005-04-29 2013-02-28 Rinat Neuroscience Corp Antibodies directed against amyloid-beta peptide and methods using same
WO2007014946A1 (en) * 2005-08-03 2007-02-08 Boehringer Ingelheim International Gmbh Substituted ethane-1,2-diamines for the treatment of alzheimer's disease ii
WO2007047305A1 (en) * 2005-10-12 2007-04-26 Elan Pharmaceuticals, Inc. Methods of treating amyloidosis using cyclopropyl derivative aspartyl protease inhibitors
JP2009511589A (ja) * 2005-10-12 2009-03-19 エラン ファーマシューティカルズ，インコーポレイテッド アリール−シクロプロピル誘導体のアスパルチルプロテアーゼ阻害剤を使用してアミロイドーシスを治療する方法
US7745484B2 (en) * 2005-11-21 2010-06-29 Amgen Inc. Beta-secretase modulators and methods of use
US7838676B2 (en) * 2005-11-21 2010-11-23 Amgen Inc. Beta-secretase modulators and methods of use
US7872009B2 (en) * 2005-11-21 2011-01-18 Amgen Inc. Beta-Secretase modulators and methods of use
CN101506236B (zh) 2005-11-30 2012-12-12 雅培制药有限公司 抗淀粉样β蛋白的单克隆抗体及其用途
BRPI0619249A2 (pt) 2005-11-30 2011-09-20 Abbott Lab anticorpos anti-globulÈmeros-aß, frações que se ligam a antìgeno destes, hibridomas correspondentes, ácidos nucléicos, vetores, células hospedeiras, métodos de produzir os ditos anticorpos, composições compreendendo os ditos anticorpos, usos dos ditos anticorpos e métodos de usar os ditos anticorpos
RU2015111675A (ru) 2005-12-12 2015-08-10 Ац Иммуне Са Специфические в отношении амилоида бета (а бета) 1-42 моноклональные антитела, обладающие терапевтическими свойствами
US8784810B2 (en) 2006-04-18 2014-07-22 Janssen Alzheimer Immunotherapy Treatment of amyloidogenic diseases
US20070292895A1 (en) * 2006-05-19 2007-12-20 Xiao-Ping Shi Assays and methods to detect beta-secretase and its activity in body fluids and tissue extracts
EP2035448A4 (de) * 2006-06-01 2010-11-03 Elan Pharm Inc Neuroaktive fragmente von app
AR062065A1 (es) * 2006-07-14 2008-10-15 Ac Immune Sa Anticuerpo humanizado
US8455626B2 (en) 2006-11-30 2013-06-04 Abbott Laboratories Aβ conformer selective anti-aβ globulomer monoclonal antibodies
MX2009006685A (es) * 2006-12-22 2009-07-27 Genentech Inc Antagonistas del dr6 y usos de los mismos en el tratamiento de trastornos neurologicos.
EP2486928A1 (de) 2007-02-27 2012-08-15 Abbott GmbH & Co. KG Verfahren zur Behandlung von Amyloidosen
US8003097B2 (en) 2007-04-18 2011-08-23 Janssen Alzheimer Immunotherapy Treatment of cerebral amyloid angiopathy
BRPI0810118A8 (pt) * 2007-04-18 2015-09-29 Janssen Alzheimer Immunotherap Método para tratar doença, método para efetuar profilaxia contra caa, uso de um agente, método para reduzir amilóide vascular em um paciente, e, kit para tratamento
WO2008137168A2 (en) * 2007-05-07 2008-11-13 True Charles W Collapsible, stackable, semi-rigid universal tank for hazardous and non-hazardous goods
US8173810B2 (en) * 2007-05-25 2012-05-08 Amgen Inc. Substituted hydroxyethyl amine compounds as beta-secretase modulators and methods of use
US8163909B2 (en) 2007-05-25 2012-04-24 Amgen Inc. Substituted hydroxyethyl amine compounds as beta-secretase modulators and methods of use
US10590391B2 (en) * 2007-06-08 2020-03-17 Wake Forest University Health Sciences Selective cell therapy for the treatment of renal failure
EP2162529B1 (de) * 2007-06-08 2019-03-27 Wake Forest University Health Sciences Selektive zelltherapie zur behandlung von nierenversagen
US8048420B2 (en) * 2007-06-12 2011-11-01 Ac Immune S.A. Monoclonal antibody
MX2009013505A (es) * 2007-06-12 2010-01-27 Ac Immune Sa Anticuerpos humanizados para amiloide beta.
US8613923B2 (en) * 2007-06-12 2013-12-24 Ac Immune S.A. Monoclonal antibody
EP2183598A1 (de) * 2007-07-13 2010-05-12 Elan Pharmaceuticals Inc. Zusammensetzungen und verfahren zur identifizierung der substratspezifität von gammasekretasehemmern
PL2182983T3 (pl) 2007-07-27 2014-10-31 Janssen Alzheimer Immunotherap Leczenie chorób amyloidowych z wykorzystaniem humanizowanych przeciwciał specyficznych względem Abeta
CN101883790B (zh) 2007-10-05 2015-09-09 基因技术公司 抗淀粉样蛋白β抗体在眼病中的用途
US20100297012A1 (en) * 2007-10-05 2010-11-25 Andrea Pfeifer Humanized antibody
JO3076B1 (ar) 2007-10-17 2017-03-15 Janssen Alzheimer Immunotherap نظم العلاج المناعي المعتمد على حالة apoe
US20090163594A1 (en) * 2007-10-31 2009-06-25 Elan Pharmaceuticals, Inc. Triple Assay System for Identifying Substrate Selectivity of Gamma Secretase Inhibitors
US7803809B2 (en) * 2008-11-12 2010-09-28 Amgen Inc. Substituted pyrano [2,3-b] pyridinamine compounds as beta-secretase modulators and methods of use
EP2231180B1 (de) * 2008-01-16 2016-08-17 Ben-gurion University Of The Negev Research And Development Authority Impfstoff für die alzheimerkrankheit
AU2009257297A1 (en) * 2008-06-12 2009-12-17 Genentech, Inc. Method for screening for compounds that inhibit neurodegeneration
CA2736130C (en) * 2008-09-11 2014-01-14 Amgen Inc. Spiro-tetracyclic ring compounds as beta-secretase modulators and methods of use
WO2010046332A1 (en) * 2008-10-20 2010-04-29 INSERM (Institut National de la Santé et de la Recherche Médicale) Method for detecting soluble amyloid precursor protein (app) alpha and/or soluble app beta
US9067981B1 (en) 2008-10-30 2015-06-30 Janssen Sciences Ireland Uc Hybrid amyloid-beta antibodies
WO2010057015A1 (en) * 2008-11-14 2010-05-20 Wake Forest University Health Sciences Kidney structures and methods of forming the same
MX2011005481A (es) 2008-11-25 2011-08-17 Biogen Idec Inc Uso de antagonistas de receptor de muerte 6 (drg6) y de p75 para promover la supervivencia de células del sistema nervioso.
CA2780319A1 (en) * 2009-11-12 2011-05-19 Genentech, Inc. A method of promoting dendritic spine density
WO2011063233A1 (en) 2009-11-23 2011-05-26 Amgen Inc. Amino heteroaryl compounds as beta-secretase modulators and methods of use
WO2011063272A1 (en) 2009-11-23 2011-05-26 Amgen Inc. Amino heteroaryl compounds as beta-secretase modulators and methods of use
EP2526092B1 (de) 2010-01-19 2014-08-06 Amgen Inc. Amino-heteraryl verbindungen als beta-secretase modulatoren und verfahren zu ihrer verwendung
US8497264B2 (en) 2010-03-15 2013-07-30 Amgen Inc. Amino-oxazines and amino-dihydrothiazine compounds as beta-secretase modulators and methods of use
US8883782B2 (en) 2010-03-15 2014-11-11 Amgen Inc. Spiro-tetracyclic ring compounds as beta-secretase modulators and methods of use
MX360403B (es) 2010-04-15 2018-10-31 Abbvie Inc Proteinas de union a amiloide beta.
RU2607368C2 (ru) 2010-07-30 2017-01-10 Ац Иммуне С.А. Безопасные и функциональные гуманизированные антитела
US8921363B2 (en) 2010-08-05 2014-12-30 Amgen Inc. Derivatives of 1 H-isoindol-3-amine, 1 H-iso-aza-indol-3amine, 3,4-dihydroisoquinolin-1-amine, and 1,4-dihydroisoquinolin-3-amine as beta-secretase inhibitors
JP6147665B2 (ja) 2010-08-14 2017-06-14 アッヴィ・インコーポレイテッド アミロイドベータ結合タンパク質
EP2643325A1 (de) 2010-11-23 2013-10-02 Amgen Inc. Spiro-amino-imidazolon- und spiro-amino-dihydro-pyrimidinonverbindungen als beta-sekretase-modulatoren und verwendungsverfahren dafür
US9346827B2 (en) 2011-02-07 2016-05-24 Amgen Inc. 5-amino-oxazepine and 5-amino-thiazepane compounds as beta secretase antagonists and methods of use
US8962859B2 (en) 2011-02-15 2015-02-24 Amgen Inc. Spiro-amino-imidazo-fused heterocyclic compounds as beta-secretase modulators and methods of use
WO2012142301A2 (en) 2011-04-12 2012-10-18 Quanterix Corporation Methods of determining a treatment protocol for and/or a prognosis of a patients recovery from a brain injury
WO2013044092A1 (en) 2011-09-21 2013-03-28 Amgen Inc. Amino-oxazines and amino-dihydrothiazine compounds as beta-secretase modulators and methods of use
CA2865756A1 (en) * 2012-02-03 2013-08-08 Shionogi & Co., Ltd. Anti-sapp.beta. antibody
WO2014059185A1 (en) 2012-10-12 2014-04-17 Amgen Inc. Amino - dihydrothiazine and amino - dioxido dihydrothiazine compounds as beta-secretase antagonists and methods of use
US9725469B2 (en) 2012-11-15 2017-08-08 Amgen, Inc. Amino-oxazine and amino-dihydrothiazine compounds as beta-secretase modulators and methods of use
US9309263B2 (en) 2013-01-29 2016-04-12 Amgen Inc. Fused multi-cyclic sulfone compounds as inhibitors of beta-secretase and methods of use thereof
WO2014134341A1 (en) 2013-03-01 2014-09-04 Amgen Inc. Perfluorinated 5,6-dihydro-4h-1,3-oxazin-2-amine compounds as beta-secretase inhibitors and methods of use
EP2964644B1 (de) 2013-03-08 2018-12-26 Amgen, Inc. Perfluorierte cyclopropylfusionierte 1,3-oxazin-2-amin-verbindungen als beta-sekretase-hemmer und verfahren zur verwendung
US9096615B2 (en) * 2013-07-30 2015-08-04 Amgen Inc. Bridged bicyclic amino thiazine dioxide compounds as inhibitors of beta-secretase and methods of use thereof
WO2016022724A1 (en) 2014-08-08 2016-02-11 Amgen Inc. Cyclopropyl fused thiazin-2-amine compounds as beta-secretase inhibitors and methods of use
EP3070096A1 (de) * 2015-03-19 2016-09-21 Ludwig-Maximilians-Universität München Peptid oder sammlung von peptiden aus amyloid-vorläuferprotein
WO2017024180A1 (en) 2015-08-06 2017-02-09 Amgen Inc. Vinyl fluoride cyclopropyl fused thiazin-2-amine compounds as beta-secretase inhibitors and methods of use
MX2019007101A (es) 2016-12-15 2019-12-16 Amgen Inc Derivados de oxazina como inhibidores de beta secretasa y metodos de uso.
CA3047287A1 (en) 2016-12-15 2018-06-21 Amgen Inc. Cyclopropyl fused thiazine derivatives as beta-secretase inhibitors and methods of use
EP3555086B1 (de) 2016-12-15 2021-09-01 Amgen Inc. 1,4-thiazin-dioxide und 1,2,4-thiadiazin-dioxid-derivate als beta-sekretase-hemmer und verfahren zur verwendung
JP7149272B2 (ja) 2016-12-15 2022-10-06 アムジエン・インコーポレーテツド β－セクレターゼ阻害剤としてのチアジン誘導体および使用方法
ES2910367T3 (es) 2016-12-15 2022-05-12 Amgen Inc Derivados de tiazina y oxazina bicíclicos como inhibidores de beta-secretasa y métodos de uso

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4492760A (en) * 1983-04-19 1985-01-08 The Wistar Institute Of Anatomy And Biology HLA D Typing assay
JPS6147500A (ja) * 1984-08-15 1986-03-07 Res Dev Corp Of Japan キメラモノクロ−ナル抗体及びその製造法
EP0173494A3 (de) * 1984-08-27 1987-11-25 The Board Of Trustees Of The Leland Stanford Junior University Chimäre Rezeptoren durch Verbindung und Expression von DNS
GB8422238D0 (en) * 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
JPS61134325A (ja) * 1984-12-04 1986-06-21 Teijin Ltd ハイブリツド抗体遺伝子の発現方法
US4666829A (en) * 1985-05-15 1987-05-19 University Of California Polypeptide marker for Alzheimer's disease and its use for diagnosis
JPS62100291A (ja) * 1985-10-28 1987-05-09 Teijin Ltd 遺伝子断片およびプラスミド
EP0247091B1 (de) * 1985-11-01 1993-09-29 Xoma Corporation Modulare einheit von antikörpergenen, daraus hergestellte antikörper und verwendung
US5223482A (en) * 1986-11-17 1993-06-29 Scios Nova Inc. Recombinant Alzheimer's protease inhibitory amyloid protein and method of use
EP0331514A3 (de) * 1988-03-04 1991-07-10 Ajinomoto Co., Inc. Prüfung der Deletion oder des Mangels an Protein von Duchenne-Muskeldystrophie
US5134062A (en) * 1988-03-22 1992-07-28 Cornell Research Foundation, Inc. Diagnosis of neuronal disorders and screening potential therapeutic agents therefor
US5262332A (en) * 1989-04-05 1993-11-16 Brigham And Women's Hospital Diagnostic method for Alzheimer's disease: examination of non-neural tissue
US5234814A (en) * 1989-06-01 1993-08-10 Du Pont Merck Pharmaceutical Company Diagnostic assay for alzheimer's disease
US5213962A (en) * 1990-04-24 1993-05-25 The Regents Of The University Of California Purification, detection and methods of use of protease Nexin-2
WO1991016628A1 (en) * 1990-04-24 1991-10-31 The Regents Of The University Of California Purification, detection and methods of use of protease nexin-2
US5385915A (en) * 1990-05-16 1995-01-31 The Rockefeller University Treatment of amyloidosis associated with Alzheimer disease using modulators of protein phosphorylation
EP0647268B1 (de) * 1990-06-15 2004-03-03 Scios Inc. Transgenes, nicht-menschliches säugetier das die amyloidbildende pathologie der alzheimerschen krankheit zeigt
AU8215391A (en) * 1990-06-29 1992-01-23 Case Western Reserve University Diagnostic and prognostic methods based on soluble derivatives of the beta amyloid protein precursor
US5200339A (en) * 1990-08-17 1993-04-06 Abraham Carmela R Proteases causing abnormal degradation of amyloid β-protein precursor
BE1003316A5 (fr) * 1990-11-27 1992-02-25 Will L F & Cie Sa Anticorps monoclonal utile pour le diagnostic de la maladie d'alzheimer, hybridome secreteur d'un tel anticorps monoclonal et procede pour sa preparation.
US5441870A (en) * 1992-04-15 1995-08-15 Athena Neurosciences, Inc. Methods for monitoring cellular processing of β-amyloid precursor protein

Also Published As

Publication number Publication date
FI944847A0 (fi) 1994-10-14
ES2206455T3 (es) 2004-05-16
US6018024A (en) 2000-01-25
DE69333225T2 (de) 2004-05-06
AU3782793A (en) 1993-11-18
JP2006051029A (ja) 2006-02-23
JPH07506967A (ja) 1995-08-03
FI944847A (fi) 1994-10-14
NO943912L (no) 1994-11-10
DE69333225D1 (de) 2003-11-06
FI111546B (fi) 2003-08-15
AU688726B2 (en) 1998-03-19
JP3974168B2 (ja) 2007-09-12
CA2118243C (en) 2009-11-03
CA2118243A1 (en) 1993-10-28
DK0638172T3 (da) 2004-02-02
EP0638172B1 (de) 2003-10-01
US5721130A (en) 1998-02-24
NO943912D0 (no) 1994-10-14
US5441870A (en) 1995-08-15
NZ251053A (en) 1996-11-26
EP0638172A1 (de) 1995-02-15
NO320067B1 (no) 2005-10-17
PT638172E (pt) 2004-02-27
EP0638172A4 (de) 1997-03-19
WO1993021526A1 (en) 1993-10-28

Similar Documents

Publication Publication Date Title
ATE251304T1 (de) Verfahren und zusammensetzungen zur beobachtung der zellulären verarbeitung von beta-amyloid- vorläuferproteinen
DE69433139D1 (de) Verfahren zur bestimmung von inhibitoren der bildung von beta-amyloidpeptid
Loh et al. Purification and characterization of a paired basic residue-specific pro-opiomelanocortin converting enzyme from bovine pituitary intermediate lobe secretory vesicles.
Flach et al. The transition from maternal to embryonic control in the 2‐cell mouse embryo.
Kreil et al. Stepwise cleavage of the pro part of Promelittin by dipeptidylpeptidase IV: evidence for a new type of precursor—product conversion
Suchanek et al. Translation of melittin messenger RNA in vitro yields a product terminating with glutaminylglycine rather than with glutaminamide.
Salvesen et al. An unusual specificity in the activation of neutrophil serine proteinase zymogens
DE3686304T2 (de) Typenspezifische papillomavirus-dns-sequenzen und peptide.
GR3019849T3 (en) Acute pancreatitis associated protein and means for the diagnosis of acute pancreatitis
Kreil Biosynthesis of Melittin, a Toxic Peptide from Bee Venom: Amino‐Acid Sequence of the Precursor
PT83255A (en) Process for the preparation of polypeptides and characteristic antibodies of papillomavirus and diagnostic method thereto
DE69510936T2 (de) Verfahren zur gewinnung von polyhydroxyalkanoaten mittels windsichtung
DE60019321D1 (de) Verfahren zum screening von inhibitoren von asp2
ATE513851T1 (de) Menschliches gen zur fruchtbarkeit entscheidend
WO2000043493A8 (en) Metalloproteinase adam 22
Bonilla Defibrinating enzyme from timber rattlesnake (Crotalus H. Horridus) venom: A potential agent for therapeutic defibrination I. Purification and properties
Henry et al. Co‐operation between metastatic tumor cells and macrophages in the degradation of basement membrane (type IV) collagen
ATE44621T1 (de) Proteinkonjugate von penicillosaeure, ihre herstellung und verwendung.
Salokangas et al. Bovine proinsulin: amino acid sequence of the C‐peptide isolated from pancreas
Rehfeld et al. Processing-Independent Analysis (PIA)-a new diagnostic tool
GB9503406D0 (en) Detection of antibody production
DAVIDSON et al. Procollagen Processing: Limited Proteolysis of COOH‐Terminal Extension Peptides by a Cathepsin‐Like Protease Secreted by Tendon Fibroblasts
Seegers et al. Note on the Electrophoresis of Thrombin.
WO1995021916A3 (en) Pp32: a newly identified cd45-associated protein
DE60121735D1 (de) Neues menschliches ulip/crmp protein und seine verwendung zur diagnose zur behandlung von krebs und von neurologischen paraneoplastischen syndromen

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0638172

Country of ref document: EP